Cobra Biologics
Mar 31, 2020
J&J’s COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott’s POC test; Cobra Bio raises $ 3.3 M
Johnson & Johnson is fast-forwarding its vaccine development program for COVID-19. The healthcare company has selected a lead vaccine candidate and is planning to begin human trials in September, with first batches available under potential emergency use authorization in the first part of 2021. The ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
